FDA spells out rules for new endpoint: Metastasis-free survival

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

It’s official, FDA is recognizing a new endpoint that seems especially well suited for prostate cancer: metastasis-free survival, or MFS for short.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

Multiple components of the healthcare and public health systems are currently under scrutiny. One of them is reportedly the U.S. Preventive Services Task Force (USPSTF: “Task Force”), established in 1984 and managed by the Agency for Healthcare Research and Quality.  It was created to maintain an ongoing evaluation of disease prevention and screening interventions that...

Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login